VativoRx, LLC

09/05/2025

As more hospitals, MSOs, and provider-led health plans step into risk-bearing models, one question keeps surfacing: Are they leaving rebate dollars behind?

Too often, rebate strategies stop at the pharmacy benefit, while medical benefit drugs like infused therapies and oncology treatments remain overlooked. For provider-led health plans, that means:

1- Untapped revenue
2 - Distorted net cost visibility
3 - Weakened leverage in negotiations

In this edition of The Rebate Report, we break down the risks and how strategic rebate management can help provider-led plans close the gap.

Have you explored the rebate potential in your medical claims? Drop a comment, we’d love to hear your perspective.

https://www.linkedin.com/pulse/provider-led-health-plans-leaving-rebate-dollars-behind-3fw3e

Hospitals and health systems are increasingly moving beyond care delivery into risk-bearing models, from Medicare Advantage plans to delegated risk through ACOs and MSOs. While this shift can strengthen financial sustainability, it often exposes a critical blind spot: rebates tied to drugs billed un

09/02/2025

🚨 FDA expands approval for Bayer’s Kerendia® (finerenone) to treat adults with heart failure (HF) and LVEF ≥40% (HFmrEF & HFpEF).

New 40mg tablet now available
16% reduction in CV death or HF events
Benefits seen across subgroups

https://vativorx.com/pharmacy-bulletin-09-02-2025/

On July 14, 2025, the US Food and Drug Administration (FDA) approved Bayer Pharmaceuticals’ Kerendia® (finerenone) for a new indication for the treatment of heart failure (HF) in adults who have left ventricular ejection fraction (LVEF) of 40% or more, including mildly reduced LVEF (HFmrEF) or pr...

08/25/2025

📢 The FDA has removed special REMS restrictions for endothelin receptor antagonist (ERA) medicines related to pregnancy risks.

Doctors can now prescribe them without REMS enrollment, though warnings on fetal risks remain in labeling.

More details here: https://vativorx.com/pharmacy-bulletin-08-25-2025/

The US Food and Drug Administration (FDA) announced the removal of Risk Evaluation and Mitigation Strategy (REMS) requirements related to embryofetal toxicity (EFT) risk for all endothelin receptor antagonist (ERA) medicines.

08/19/2025

📊 New Numbers. New Strategy.
The latest reports from
are in — and the specialty drug landscape is shifting fast.

While most health systems and payers are tracking trends, few are turning data into rebate opportunities. That's where strategic rebate management makes the difference.

In this edition of The Rebate Report, we break down what these trends mean for medical and pharmacy rebates — and how forward-thinking organizations are adapting their approach.

🧠 Let’s talk data, strategy, and smarter savings.

👇 Read the insights
:
https://www.linkedin.com/pulse/medical-rebates-take-center-stage-unlocking-hidden-value-2slee

08/18/2025

🚨 Big news for cancer patients: The FDA has removed special REMS restrictions on CAR-T therapies (like Yescarta®, Abecma®, Breyanzi® & more).

This means easier access, fewer barriers for treatment centers (even in rural areas), and potentially double the patient reach.

More updates here: https://vativorx.com/pharmacy-bulletin-08-18-2025/

On June 27, 2025, the US Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved B-cell maturation antigen (BCMA)- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies, including Abecma® (idecabtagene v...

08/14/2025

Datroway® Now Approved for Certain Lung Cancer Patients
The FDA has given accelerated approval to Datroway® for adults with advanced EGFR-mutated non-small cell lung cancer 🫁 who’ve already tried targeted therapy and chemo.

This targeted treatment helps deliver cancer-fighting medicine directly to tumor cells. In studies, nearly half of patients saw their cancer shrink, with results lasting about 6.5 months on average.

Already used for breast cancer, Datroway® is now bringing hope to more patients.

More updates here: https://vativorx.com/pharmacy-bulletin-08-14-2025/

On June 23, 2025, the US Food and Drug Administration (FDA) granted accelerated approval to Daiichi Sankyo and AstraZeneca’s Datroway® (datopotamab deruxtecan-dlnk) for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) wh...

08/13/2025

Steqeyma® – Easier Dosing for Kids with Psoriasis or PsA

Parents now have another option for kids living with psoriasis or psoriatic arthritis 🙌. A new vial size of Steqeyma® makes dosing simpler for smaller patients.

Read Now: https://vativorx.com/pharmacy-bulletin-08-13-2025/

The US Food and Drug Administration (FDA) granted approval on June 13, 2025, for a new presentation of Celltrion’s Steqeyma® (ustekinumab-stba), a biosimilar to Janssen Pharmaceutical’s Stelara® (ustekinumab).

08/04/2025

🚨 FDA approves Widaplik™, the 1st triple low-dose combo pill for hypertension (telmisartan/amlodipine/indapamide). Shown to improve BP control vs dual combos. Once-daily dose, launch expected Q4 2025.

👉 https://vativorx.com/pharmacy-bulletin-08-04-2025/

On June 9, 2025, the US Food and Drug Administration (FDA) approved George Medicines’ Widaplik™ (telmisartan, amlodipine, indapamide) for the treatment of hypertension in adults, including as initial treatment.

07/21/2025

We’re live at the Health Care Administrators Association® (HCAA) TPA Summit in Dallas, and we’re helping TPAs turn overlooked J-code claims into real rebate revenue.

✅ Reclaim value from existing claims
✅ Strengthen client & broker relationships
✅ Offset admin costs with no disruption

Stop by Booth #5 to meet Jim Haidet and Bruce Marwil and learn how our tech-enabled, HIPAA-compliant platform makes rebate capture seamless and impactful.

Let’s rethink your rebate strategy, together.



https://www.linkedin.com/feed/update/urn:li:activity:7353061871416922112

07/18/2025

💡 New: The 2025 rebate gap you may not see — but are definitely paying for.

Most healthcare payers lean on rebates to offset drug costs, but according to PSG’s latest trends report, there’s one major flaw in how they’re doing it: lack of coordination between pharmacy and medical benefit rebates.

This edition of The Rebate Report unpacks:
• What the data says about shifting drug cost pressures
• Why medical rebate eligibility often gets overlooked
• How forward-looking plans are adapting their rebate approach

🔍 Plus, how to tell if your organization is leaving money on the table.

👇 Read the newsletter & share your take — are your rebates truly working together?

https://www.linkedin.com/pulse/rebates-dont-work-silos-vativorx-llc-imgee

07/16/2025

📢 FDA approves Moderna’s next-gen COVID vax mNEXSPIKE® for adults 65+ & high-risk 12–64 y/o. Offers longer shelf life & easier storage vs Spikevax®. Stronger immune response & fewer side effects seen in trials. Launch expected for 2025-26 season.

👉 https://vativorx.com/pharmacy-bulletin-07-16-2025/

On May 31, 2025, the US Food and Drug Administration (FDA) approved Moderna’s mNEXSPIKE® (COVID-19 vaccine, mRNA-1283) for use in all adults 65 years and older, and individuals between 12 years and 64 years of age with at least one or more underlying conditions that puts them at risk for severe o...

07/10/2025

Most TPAs aren’t capturing rebates tied to physician-administered drugs — and that’s lost value for clients.

VativoRx helps unlock a high-impact savings channel hidden in your current claims. No new systems, no disruption.

Catch us at Booth #5 at in Dallas, July 21–23!